Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Search

Page Path
HOME > Search
7 "Guidelines"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Statements
Role of 5-aminosalicylic acid in ulcerative colitis management in 8 Asian territories: a physician survey
Julajak Limsrivilai, Allen Yu-hung Lai, Silvia T. H. Li, Murdani Abdullah, Raja Affendi Raja Ali, Satimai Aniwan, Hoang Huu Bui, Jen-Wei Chou, Ida Normiha Hilmi, Wee Chian Lim, Jose Sollano, Michelle Mui Hian Teo, Shu-Chen Wei, Wai Keung Leung
Received June 8, 2024  Accepted October 15, 2024  Published online January 6, 2025  
DOI: https://doi.org/10.5217/ir.2024.00085    [Epub ahead of print]
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Clinical guidelines typically endorse conventional therapies such as 5-aminosalicylic acid (5-ASA) as the mainstay of ulcerative colitis management. However, the degree of adoption and application of guideline recommendations by physicians within Asia remains unclear. This study aims to understand the prescribing patterns of 5-ASA and implementation of current guideline recommendations across Asian clinical practice. A physician survey was conducted among inflammatory bowel disease specialists in 8 Asian territories to understand practices and preferences in ulcerative colitis management, focusing on the use of 5-ASA and concordance with guideline recommendations. Survey findings were validated by country experts in diverse healthcare settings. Subgroup analyses stratified data by income levels and treatment reimbursement status. Ninety-eight valid responses were received from inflammatory bowel disease specialists or gastroenterologists among 8 economic entities. Significant differences were found in clinical practices and treatment preferences for ulcerative colitis management among different income-level and government-subsidy groups. Survey results are summarized in 8 findings that illustrate trends in 5-ASA use and guideline implementation across Asian territories. This study emphasizes socioeconomic factors that impact the adoption of guideline recommendations in real-world practice. Our findings indicate an eclectic approach to guideline implementation across Asia, based on resource availability and feasibility of treatment goals.
  • 1,391 View
  • 126 Download
Close layer
IBD
Management of Crohn’s disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023
Jia-Feng Wu, Hsu-Heng Yen, Horng-Yuan Wang, Ting-An Chang, Chung-Hsin Chang, Chen-Wang Chang, Te-Hsin Chao, Jen-Wei Chou, Yenn-Hwei Chou, Chiao-Hsiung Chuang, Wen-Hung Hsu, Tzu-Chi Hsu, Tien-Yu Huang, Tsung-I Hung, Puo-Hsien Le, Chun-Che Lin, Chun-Chi Lin, Ching-Pin Lin, Jen-Kou Lin, Wei-Chen Lin, Yen-Hsuan Ni, Ming-Jium Shieh, I-Lun Shih, Chia-Tung Shun, Tzung-Jiun Tsai, Cheng-Yi Wang, Meng-Tzu Weng, Jau-Min Wong, Deng-Chyang Wu, Shu-Chen Wei
Intest Res 2024;22(3):250-285.   Published online July 29, 2024
DOI: https://doi.org/10.5217/ir.2024.00060
AbstractAbstract PDFPubReaderePub
Crohn’s disease (CD) is a chronic, fluctuating inflammatory condition that primarily affects the gastrointestinal tract. Although the incidence of CD in Taiwan is lower than that in Western countries, the severity of CD presentation appears to be similar between Asia and the West. This observation indicates the urgency for devising revised guidelines tailored to the unique reimbursement system, and patient requirements in Taiwan. The core objectives of these updated guidelines include the updated treatment choices and the integration of the treat-to-target strategy into CD management, promoting the achievement of deep remission to mitigate complications and enhance the overall quality of life. Given the diversity in disease prevalence, severity, insurance policies, and access to medical treatments in Taiwan, a customized approach is imperative for formulating these guidelines. Such tailored strategies ensure that international standards are not only adapted but also optimized to local contexts. Since the inception of its initial guidelines in 2017, the Taiwan Society of Inflammatory Bowel Disease (TSIBD) has acknowledged the importance of continuous revisions for incorporating new therapeutic options and evolving disease management practices. The latest update leverages international standards and recent research findings focused on practical implementation within the Taiwanese healthcare system.
  • 4,163 View
  • 207 Download
Close layer
IBD
Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023
Hsu-Heng Yen, Jia-Feng Wu, Horng-Yuan Wang, Ting-An Chang, Chung-Hsin Chang, Chen-Wang Chang, Te-Hsin Chao, Jen-Wei Chou, Yenn-Hwei Chou, Chiao-Hsiung Chuang, Wen-Hung Hsu, Tzu-Chi Hsu, Tien-Yu Huang, Tsung-I Hung, Puo-Hsien Le, Chun-Che Lin, Chun-Chi Lin, Ching-Pin Lin, Jen-Kou Lin, Wei-Chen Lin, Yen-Hsuan Ni, Ming-Jium Shieh, I-Lun Shih, Chia-Tung Shun, Tzung-Jiun Tsai, Cheng-Yi Wang, Meng-Tzu Weng, Jau-Min Wong, Deng-Chyang Wu, Shu-Chen Wei
Intest Res 2024;22(3):213-249.   Published online July 29, 2024
DOI: https://doi.org/10.5217/ir.2023.00050
AbstractAbstract PDFPubReaderePub
Ulcerative colitis (UC) is a chronic inflammation of the gastrointestinal tract and is characterized by alternating periods of inflammation and remission. Although UC incidence is lower in Taiwan than in Western countries, its impact remains considerable, demanding updated guidelines for addressing local healthcare challenges and patient needs. The revised guidelines employ international standards and recent research, emphasizing practical implementation within the Taiwanese healthcare system. Since the inception of the guidelines in 2017, the Taiwan Society of Inflammatory Bowel Disease has acknowledged the need for ongoing revisions to incorporate emerging therapeutic options and evolving disease management practices. This updated guideline aims to align UC management with local contexts, ensuring comprehensive and context-specific recommendations, thereby raising the standard of care for UC patients in Taiwan. By adapting and optimizing international protocols for local relevance, these efforts seek to enhance health outcomes for patients with UC.

Citations

Citations to this article as recorded by  
  • Short-term and long-term outcomes of acute severe ulcerative colitis in Taiwan: a multicenter study with pre- and post-biologics comparison
    Wei-Chen Lin, Chun-Chi Lin, Wen-Hung Hsu, Feng-Fan Chiang, Chen-Wang Chang, Tzu-Chi Hsu, Deng-Chyang Wu, Horng-Yuan Wang, Jau-Min Wong, Shu-Chen Wei
    Intestinal Research.2025;[Epub]     CrossRef
  • Endoscopic Techniques for Colorectal Neoplasia Surveillance in Inflammatory Bowel Disease: A Systematic Review and Network Meta‐Analysis
    Chih‐Wen Huang, Hsu‐Heng Yen, Yang‐Yuan Chen
    United European Gastroenterology Journal.2025;[Epub]     CrossRef
  • Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Systematic Review and Network Meta-analysis
    Chih-Wen Huang, Hsu-Heng Yen, Yang-Yuan Chen
    Journal of Crohn's and Colitis.2024; 18(12): 2063.     CrossRef
  • High prevalence of vitamin D deficiency in Taiwanese patients with inflammatory bowel disease
    Chen-Ta Yang, Hsu-Heng Yen, Pei-Yuan Su, Yang-Yuan Chen, Siou-Ping Huang
    Scientific Reports.2024;[Epub]     CrossRef
  • 5,378 View
  • 252 Download
  • 4 Crossref
Close layer
Reviews
Colorectal neoplasia
Summary and comparison of recently updated post-polypectomy surveillance guidelines
Yoon Suk Jung
Intest Res 2023;21(4):443-451.   Published online October 26, 2023
DOI: https://doi.org/10.5217/ir.2023.00107
AbstractAbstract PDFPubReaderePub
Recently, updated guidelines for post-polypectomy surveillance have been published by the U.S. Multi‐Society Task Force (USMSTF), the British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England (BSG/ACPGBI/PHE), the European Society of Gastrointestinal Endoscopy (ESGE), the Japan Gastroenterological Endoscopy Society (JGES), and the Korean Multi-Society Taskforce Committee. This review summarizes and compares the updated recommendations of these 5 guidelines. There are some differences between the guidelines for the recommended post-polypectomy surveillance intervals. In particular, there are prominent differences between the guidelines for 1–4 tubular adenomas < 10 mm with low-grade dysplasia (nonadvanced adenomas [NAAs]) and tubulovillous or villous adenomas. The USMSTF, JGES, and Korean guidelines recommend colonoscopic surveillance for patients with 1–4 NAAs and those with tubulovillous or villous adenomas, whereas the BSG/ACPGBI/PHE and ESGE guidelines do not recommend endoscopic surveillance for such patients. Surveillance recommendations for patients with serrated polyps (SPs) are limited. Although the USMSTF guidelines provide specific recommendations for patients who have undergone SPs removal, these are weak and based on very lowquality evidence. Future studies should examine this topic to better guide the surveillance recommendations for patients with SPs. For countries that do not have separate guidelines, we hope that this review article will help select the most appropriate guidelines as per each country’s healthcare environment.

Citations

Citations to this article as recorded by  
  • Influence of Lifestyles on Polyp Burden and Cancer Development in Hereditary Colorectal Cancer Syndromes
    Hye Kyung Hyun, Ji Soo Park, Jihye Park, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim
    Journal of Gastroenterology and Hepatology.2025; 40(2): 433.     CrossRef
  • Frequency and Risk Factors of Advanced Neoplasia in Korean Inflammatory Bowel Disease Patients with Low-grade Dysplasia
    Yong Eun Park, Kyeong Ok Kim, Dong Hyun Kim, Soo-Kyung Park, Yoo Jin Lee, Chang Kyun Lee
    The Korean Journal of Gastroenterology.2025; 85(1): 34.     CrossRef
  • The impact of COVID-19 on clinical practices of colorectal cancer in South Korea
    Kwang Woo Kim, Hyoun Woo Kang
    Intestinal Research.2025; 23(1): 6.     CrossRef
  • Annual Blood Tests Are an Acceptable form of Surveillance to Supplement Colonoscopies for Colorectal Cancer
    Rishabh Goyal, Carlene J. Wilson, Ingrid H. Flight, Charles Cock, Graeme P. Young, Molla M. Wassie, Sarah Cohen-Woods, Erin L. Symonds, Maddison Dix
    Digestive Diseases and Sciences.2025; 70(4): 1486.     CrossRef
  • Assessing Patient Preferences and Response to Extended Colonoscopy Intervals in a Colorectal Cancer Surveillance Program
    Maddison Dix, Syme Aftab, Graeme P. Young, Carlene J. Wilson, Kalindra Simpson, Charles Cock, Erin L. Symonds
    Digestive Diseases and Sciences.2025; 70(4): 1328.     CrossRef
  • Developing a Strategy for Prevention of Avoidable Postcolonoscopy Colorectal Cancers: Current and Future Perspectives
    Nanette S. Van roermund, Joep E.G. Ijspeert, Evelien Dekker
    Gastroenterology.2025;[Epub]     CrossRef
  • Causal association between telomere length and colorectal polyps: A bidirectional two-sample Mendelian randomization study
    Yin Zhang, Jiaying Wang, Mingyu Zheng, Huanwei Qu, Shuya Yang, Fuzhou Han, Nan Yao, Wenqiang Li, Jun Qu
    Medicine.2024; 103(1): e36867.     CrossRef
  • Screening and surveillance for hereditary colorectal cancer
    Hee Man Kim, Tae Il Kim
    Intestinal Research.2024; 22(2): 119.     CrossRef
  • Screening and Surveillance of Colorectal Cancer: A Review of the Literature
    Marcello Maida, Dushyant Singh Dahiya, Yash R. Shah, Angad Tiwari, Harishankar Gopakumar, Ishaan Vohra, Aqsa Khan, Fouad Jaber, Daryl Ramai, Antonio Facciorusso
    Cancers.2024; 16(15): 2746.     CrossRef
  • 3,715 View
  • 201 Download
  • 9 Web of Science
  • 9 Crossref
Close layer
Cancer
Korean Guidelines for Postpolypectomy Colonoscopic Surveillance: 2022 revised edition
Su Young Kim, Min Seob Kwak, Soon Man Yoon, Yunho Jung, Jong Wook Kim, Sun-Jin Boo, Eun Hye Oh, Seong Ran Jeon, Seung-Joo Nam, Seon-Young Park, Soo-Kyung Park, Jaeyoung Chun, Dong Hoon Baek, Mi-Young Choi, Suyeon Park, Jeong-Sik Byeon, Hyung Kil Kim, Joo Young Cho, Moon Sung Lee, Oh Young Lee, Korean Society of Gastrointestinal Endoscopy, Korean Society of Gastroenterology, Korean Association for the Study of Intestinal Diseases
Intest Res 2023;21(1):20-42.   Published online January 31, 2023
DOI: https://doi.org/10.5217/ir.2022.00096
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Colonoscopic polypectomy is effective in decreasing the incidence and mortality of colorectal cancer (CRC). Premalignant polyps discovered during colonoscopy are associated with the risk of metachronous advanced neoplasia. Postpolypectomy surveillance is the most important method for managing advanced metachronous neoplasia. A more efficient and evidence-based guideline for postpolypectomy surveillance is required because of the limited medical resources and concerns regarding colonoscopy complications. In these consensus guidelines, an analytic approach was used to address all reliable evidence to interpret the predictors of CRC or advanced neoplasia during surveillance colonoscopy. The key recommendations state that the high-risk findings for metachronous CRC following polypectomy are as follows: adenoma ≥10 mm in size; 3 to 5 (or more) adenomas; tubulovillous or villous adenoma; adenoma containing high-grade dysplasia; traditional serrated adenoma; sessile serrated lesion containing any grade of dysplasia; serrated polyp of at least 10 mm in size; and 3 to 5 (or more) sessile serrated lesions. More studies are needed to fully comprehend the patients who are most likely to benefit from surveillance colonoscopy and the ideal surveillance interval to prevent metachronous CRC.

Citations

Citations to this article as recorded by  
  • Survey of the Actual Practices Used for Endoscopic Removal of Colon Polyps in Korea: A Comparison with the Current Guidelines
    Jeongseok Kim, Tae-Geun Gweon, Min Seob Kwak, Su Young Kim, Seong Jung Kim, Hyun Gun Kim, Sung Noh Hong, Eun Sun Kim, Chang Mo Moon, Dae Seong Myung, Dong-Hoon Baek, Shin Ju Oh, Hyun Jung Lee, Ji Young Lee, Yunho Jung, Jaeyoung Chun, Dong-Hoon Yang, Eun R
    Gut and Liver.2025; 19(1): 77.     CrossRef
  • The impact of COVID-19 on clinical practices of colorectal cancer in South Korea
    Kwang Woo Kim, Hyoun Woo Kang
    Intestinal Research.2025; 23(1): 6.     CrossRef
  • Colorectal Cancer after Colonoscopy: Causes and Prevention Strategies
    Seongwoo Choi, Yunho Jung
    The Korean Journal of Medicine.2025; 100(1): 19.     CrossRef
  • The histologic features, molecular features, detection and management of serrated polyps: a review
    Jin-Dong Wang, Guo-Shuai Xu, Xin-Long Hu, Wen-Qiang Li, Nan Yao, Fu-Zhou Han, Yin Zhang, Jun Qu
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Screening and surveillance for hereditary colorectal cancer
    Hee Man Kim, Tae Il Kim
    Intestinal Research.2024; 22(2): 119.     CrossRef
  • Prediction of Lymph Node Metastasis in T1 Colorectal Cancer Using Artificial Intelligence with Hematoxylin and Eosin-Stained Whole-Slide-Images of Endoscopic and Surgical Resection Specimens
    Joo Hye Song, Eun Ran Kim, Yiyu Hong, Insuk Sohn, Soomin Ahn, Seok-Hyung Kim, Kee-Taek Jang
    Cancers.2024; 16(10): 1900.     CrossRef
  • Strategies to improve screening colonoscopy quality for the prevention of colorectal cancer
    Joo Hye Song, Eun Ran Kim
    The Korean Journal of Internal Medicine.2024; 39(4): 547.     CrossRef
  • Efficacy of Oral Sulfate Tablet and 2 L-Polyethylene Glycol With Ascorbic Acid for Bowel Preparation: A Prospective Randomized KASID Multicenter Trial
    Yunho Jung, Hyun Gun Kim, Dong-Hoon Yang, Hyoun Woo Kang, Jae Jun Park, Dong Hoon Baek, Jaeyoung Chun, Tae-Geun Gweon, Hyeon Jeong Goong, Min Seob Kwak, Hyun Jung Lee, Soo-Kyung Park, Jong Hoon Lee
    Journal of Korean Medical Science.2024;[Epub]     CrossRef
  • Post-colonoscopy Colorectal Cancer: Causes and Prevention
    Jong Yoon Lee
    Journal of Digestive Cancer Research.2024; 12(3): 160.     CrossRef
  • Korean Guidelines for Postpolypectomy Colonoscopic Surveillance: 2022 Revision
    Su Young Kim
    The Korean Journal of Medicine.2023; 98(3): 102.     CrossRef
  • Clinical characteristics and risk factors related to polyposis recurrence and advanced neoplasm development among patients with non-hereditary colorectal polyposis
    Jihun Jang, Jihye Park, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim
    Intestinal Research.2023; 21(4): 510.     CrossRef
  • Summary and comparison of recently updated post-polypectomy surveillance guidelines
    Yoon Suk Jung
    Intestinal Research.2023; 21(4): 443.     CrossRef
  • Strategy for post-polypectomy colonoscopy surveillance: focus on the revised Korean guidelines
    Yong Soo Kwon, Su Young Kim
    Journal of the Korean Medical Association.2023; 66(11): 652.     CrossRef
  • 8,950 View
  • 281 Download
  • 13 Crossref
Close layer
Statement
IBD
Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy–Access to Rapid Treatment (iSTART) approach
Silvio Danese, Rupa Banerjee, JR Fraser Cummings, Iris Dotan, Paulo G Kotze, Rupert Wing Loong Leong, Kristine Paridaens, Laurent Peyrin-Biroulet, Glyn Scott, Gert Van Assche, Jan Wehkamp, Jesús K Yamamoto-Furusho
Intest Res 2018;16(4):522-528.   Published online October 16, 2018
DOI: https://doi.org/10.5217/ir.2018.00073
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Symptomatic ulcerative colitis (UC) can be a chronic, disabling condition. Flares in disease activity are associated with many of the negative impacts of mild-to-moderate UC. Rapid resolution of flares can provide benefits to patients and healthcare systems. i Support Therapy–Access to Rapid Treatment (iSTART) introduces patient-centered care for mild-to-moderate UC. iSTART provides patients with the ability to self-assess symptomology and self-start a short course of second-line treatment when necessary. An international panel of experts produced consensus statements and recommendations. These were informed by evidence from systematic reviews on the epidemiology, mesalazine (5-ASA) treatment, and patient use criteria for second-line therapy in UC. Optimized 5-ASA is the first-line treatment in all clinical guidelines, but may not be sufficient to induce remission in all patients. Corticosteroids should be prescribed as second-line therapy when needed, with budesonide MMX® being a preferred steroid option. Active involvement of suitable patients in management of UC flares has the potential to improve therapy, with patients able to show good accuracy for flare self-assessment using validated tools. There is a place in the UC treatment pathway for an approach such as iSTART, which has the potential to provide patient, clinical and economic benefits.

Citations

Citations to this article as recorded by  
  • Sodium orthovanadate protects against ulcerative colitis and associated liver damage in mice: insights into modulations of Nrf2/Keap1 and NF-κB pathways
    Gurpreet Kaur, Ajay Singh Kushwah
    Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(2): 1557.     CrossRef
  • Management and treatment optimization of patients with mild to moderate ulcerative colitis
    Ferdinando D’Amico, Ernesto Fasulo, Vipul Jairath, Kristine Paridaens, Laurent Peyrin-Biroulet, Silvio Danese
    Expert Review of Clinical Immunology.2024; 20(3): 277.     CrossRef
  • Practical management of mild-to-moderate ulcerative colitis: an international expert consensus
    Ferdinando D’Amico, Fernando Magro, Axel Dignass, Sameer Al Awadhi, Ana Gutierrez Casbas, Natália Sousa Freitas Queiroz, Grażyna Rydzewska, Byong Duk Ye, Zhihua Ran, Ailsa Hart, Vipul Jairath, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese
    Expert Review of Gastroenterology & Hepatology.2024; 18(8): 421.     CrossRef
  • Framework of IBD Care Delivery Across Ages
    Stefan Delen, Susanna Jaghult, Irina Blumenstein, Lieven Pouillon, Peter Bossuyt
    Journal of Crohn's and Colitis.2024; 18(Supplement): ii55.     CrossRef
  • Effectiveness of Mesalamine in Patients With Ulcerative Colitis: A Systematic Review
    Yurianna Santos, Arturo P Jaramillo
    Cureus.2023;[Epub]     CrossRef
  • Encoding bacterial colonization and therapeutic modality by wrapping with an adhesive drug-loadable nanocoating
    Huilong Luo, Feng Wu, Xinyue Wang, Sisi Lin, Mengmeng Zhang, Zhenping Cao, Jinyao Liu
    Materials Today.2023; 62: 98.     CrossRef
  • iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis
    Ferdinando D’Amico, Fernando Magro, Benedicte Caron, Axel Dignass, Vipul Jairath, Ailsa Hart, Paulo Gustavo Kotze, Kristine Paridaens, Sameer Al Awadhi, Taku Kobayashi, Britta Siegmund, Laurent Peyrin-Biroulet, Silvio Danese
    Journal of Clinical Medicine.2023; 12(3): 1142.     CrossRef
  • A review article of inflammatory bowel disease treatment and pharmacogenomics
    Nashwa Eltantawy, Islam Abd El-Hamid El-Zayyadi, Ahmed A. Elberry, Layla M. Salah, Mohamed E. A. Abdelrahim, Amira B. Kassem
    Beni-Suef University Journal of Basic and Applied Sciences.2023;[Epub]     CrossRef
  • Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis
    Axel U. Dignass, Kristine Paridaens, Sameer Al Awadhi, Jakob Begun, Jae Hee Cheon, John R. Fullarton, Edouard Louis, Fernando Magro, Juan Ricardo Marquez, Alexander R. Moschen, Neeraj Narula, Grazyna Rydzewska, Simon P. L. Travis
    Scandinavian Journal of Gastroenterology.2022; 57(4): 424.     CrossRef
  • Needs and preferences of patients regarding atopic dermatitis care in the era of new therapeutic options: a qualitative study
    Linde E. M. de Wijs, Sven van Egmond, Arjan C. A. Devillers, Tamar Nijsten, DirkJan Hijnen, Marjolein Lugtenberg
    Archives of Dermatological Research.2022; 315(1): 75.     CrossRef
  • Mesalazine in the induction of clinical and endoscopic remission of mild and moderate ulcerative colitis
    M. V. Shapina
    Meditsinskiy sovet = Medical Council.2022; (15): 90.     CrossRef
  • Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
    Giovanni Maconi, Deborah Camatta, Rosanna Cannatelli, Francesca Ferretti, Anna Carvalhas Gabrielli, Sandro Ardizzone
    Therapeutics and Clinical Risk Management.2021; Volume 17: 285.     CrossRef
  • High Serum Osmolality May Predict the Disease Severity in Patients with Acute Ulcerative Colitis
    Abdussamed VURAL, Aslı VURAL, Selahattin VURAL, Selim TURFAN, Ahmet Cumhur DÜLGER
    Online Türk Sağlık Bilimleri Dergisi.2020; 5(2): 324.     CrossRef
  • The Efficacy and Safety of Mesalamine and Probiotics in Mild‐to‐Moderate Ulcerative Colitis: A Systematic Review and Meta‐Analysis
    Chunying Tian, Yang Huang, Xiaoxia Wu, Chuhan Xu, Huaien Bu, Hongwu Wang, Jairo Kennup Bastos
    Evidence-Based Complementary and Alternative Medicine.2020;[Epub]     CrossRef
  • Teleconsulta en la pandemia por Coronavirus: desafíos para la telemedicina pos-COVID-19
    Juan Ricardo Márquez Velásquez
    Revista Colombiana de Gastroenterología.2020; 35(Supl. 1): 5.     CrossRef
  • Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
    Virginia Solitano, Ferdinando D’Amico, Gionata Fiorino, Kristine Paridaens, Laurent Peyrin-Biroulet, Silvio Danese
    Journal of Clinical Medicine.2020; 9(9): 2905.     CrossRef
  • A clinical case of ulcerative colitis in a patient with viral hepatitis
    E. D. Kosmachova, M. S. Iakovenko, K. A. Yumukian
    South Russian Journal of Therapeutic Practice.2020; 1(3): 95.     CrossRef
  • Case Report on Ulcerative Colitis in 16 year girl
    MD.Salma MD.Salma, Y.Siva Y.Siva , , J.Bhargava Narendra , J.Bhargava Narendra
    World Journal of Current Medical and Pharmaceutical Research.2020; : 287.     CrossRef
  • 12,032 View
  • 568 Download
  • 16 Web of Science
  • 18 Crossref
Close layer
Review
Second Korean guidelines for the management of ulcerative colitis
Chang Hwan Choi, Won Moon, You Sun Kim, Eun Soo Kim, Bo-In Lee, Yunho Jung, Yong Sik Yoon, Heeyoung Lee, Dong Il Park, Dong Soo Han
Intest Res 2017;15(1):7-37.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.7
AbstractAbstract PDFPubReaderePub

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by a relapsing and remitting course. The direct and indirect costs of the treatment of UC are high, and the quality of life of patients is reduced, especially during exacerbation of the disease. The incidence and prevalence of UC in Korea are still lower than those of Western countries, but have been rapidly increasing during the past decades. Various medical and surgical therapies, including biologics, are currently used for the management of UC. However, many challenging issues exist, which sometimes lead to differences in practice between clinicians. Therefore, the IBD study group of the Korean Association for the Study of Intestinal Diseases established the first Korean guidelines for the management of UC in 2012. This is an update of the first guidelines. It was generally made by the adaptation of several foreign guidelines as was the first edition, and encompasses treatment of active colitis, maintenance of remission, and indication of surgery for UC. The specific recommendations are presented with the quality of evidence and classification of recommendations.

Citations

Citations to this article as recorded by  
  • Comparison of Effects on 6-Thioguanine Nucleotides According to Mesalazine Formulation in Pediatric Patients with Ulcerative Colitis
    Hansol Kim, Yoon Zi Kim, Seon Young Kim, Yon Ho Choe, Mi Jin Kim
    Clinical Therapeutics.2025; 47(3): 196.     CrossRef
  • Comparison of 1‐Year Clinical Course in Patients With Newly Diagnosed Inflammatory Bowel Disease Between Vietnam and Korea: A Multinational, Multicenter Retrospective Cohort Study
    Luan Minh Dang, Eun Soo Kim, Kyeong Ok Kim, Yoo Jin Lee, Hoang Huu Bui, Chuong Dinh Nguyen, Chi Thi Nguyen, Nam Hoai Nguyen, Hien Thi‐Thu Nguyen, Nga Thi Dinh, Lien Thi‐Phuong Nguyen, Khien Van Vu, Minh Cuong Duong
    JGH Open.2025;[Epub]     CrossRef
  • The impact of gut microbiome enterotypes on ulcerative colitis: identifying key bacterial species and revealing species co-occurrence networks using machine learning
    Xuangao Wu, Ting Zhang, TianShun Zhang, Sunmin Park
    Gut Microbes.2024;[Epub]     CrossRef
  • Complementary Therapeutic Effect of Fecal Microbiota Transplantation in Ulcerative Colitis after the Response to Anti-Tumor Necrosis Factor Alpha Agent Was Lost: A Case Report
    Jongbeom Shin, Ga Hyeon Baek, Boram Cha, Soo-Hyun Park, Jung-Hwan Lee, Jun-Seob Kim, Kye Sook Kwon
    Biomedicines.2024; 12(4): 800.     CrossRef
  • Anti‐inflammatory and anti‐hyperalgesic effects induced by an aqueous aged black garlic extract in rodent models of ulcerative colitis and colitis‐associated visceral pain
    Maria Loreta Libero, Elena Lucarini, Lucia Recinella, Clara Ciampi, Serena Veschi, Anna Piro, Annalisa Chiavaroli, Alessandra Acquaviva, Nilofar Nilofar, Giustino Orlando, Daniele Generali, Carla Ghelardini, Lorenzo di Cesare Mannelli, Antonio J. Montero‐
    Phytotherapy Research.2024; 38(8): 4177.     CrossRef
  • Risks of Cancer Associated with Therapeutic Drugs for Inflammatory Bowel Disease
    Won Moon, Jae Jun Park
    The Korean Journal of Gastroenterology.2024; 83(6): 233.     CrossRef
  • Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-Tumor Necrosis Factors
    Sang Un Kim, Hyun Seok Lee
    The Korean Journal of Gastroenterology.2024; 84(2): 35.     CrossRef
  • Inflammatory Bowel Disease: Pathophysiology, Treatment, and Disease Modeling
    Jiryeon Jang, Sehoon Jeong
    BioChip Journal.2023; 17(4): 403.     CrossRef
  • Factors associated with the prescription of probiotics in patients with inflammatory bowel disease: a cross-sectional study
    Joo Kyung Kim, Jae Hee Cheon
    Journal of Yeungnam Medical Science.2023; 40(1): 37.     CrossRef
  • Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
    Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim
    Intestinal Research.2023; 21(1): 61.     CrossRef
  • Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study
    Seung Hwan Shin, Kyunghwan Oh, Sung Noh Hong, Jungbok Lee, Shin Ju Oh, Eun Soo Kim, Soo-Young Na, Sang-Bum Kang, Seong-Joon Koh, Ki Bae Bang, Sung-Ae Jung, Sung Hoon Jung, Kyeong Ok Kim, Sang Hyoung Park, Suk-Kyun Yang, Chang Hwan Choi, Byong Duk Ye
    Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
  • Low Serum Hepcidin Levels in Patients with Ulcerative Colitis – Implications for Treatment of Co-existent Iron-Deficiency Anemia
    Jagadish Ramasamy, Chinmai Jagadish, Abitha Sukumaran, Joe Varghese, Thenmozhi Mani, A. J. Joseph, Ebby George Simon, Molly Jacob
    Inflammation.2023; 46(6): 2209.     CrossRef
  • Screening for Chemical Characterization and Pharmacological Properties of Different Extracts from Nepeta italica
    Alessandra Acquaviva, Simonetta Cristina Di Simone, Nilofar, Abdelhakim Bouyahya, Gokhan Zengin, Lucia Recinella, Sheila Leone, Luigi Brunetti, Abdullahi Ibrahim Uba, Osman Guler, Maruf Balos, Ugur Cakilcioğlu, Luigi Menghini, Claudio Ferrante, Giustino
    Plants.2023; 12(15): 2785.     CrossRef
  • Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
    Eun Mi Song, Soo-Young Na, Sung Noh Hong, Siew Chien Ng, Tadakazu Hisamatsu, Byong Duk Ye
    Intestinal Research.2023; 21(3): 339.     CrossRef
  • Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
    Yu Kyung Jun, Seong-Joon Koh, Dae Seong Myung, Sang Hyoung Park, Choon Jin Ooi, Ajit Sood, Jong Pil Im
    Intestinal Research.2023; 21(3): 353.     CrossRef
  • Advancements in the Management of Moderate-to-Severe Ulcerative Colitis: A Revised 2023 Korean Treatment Guidelines
    Soo-Young Na
    The Korean Journal of Medicine.2023; 98(5): 223.     CrossRef
  • Comparison of 1-Year Colectomy Risk Between the US and Korean Patients with Acute Severe Ulcerative Colitis: A Propensity Score Matching Analysis
    Eun Soo Kim, Kyeong Ok Kim, Byung Ik Jang, Eun Young Kim, Yoo Jin Lee, Hyun Seok Lee, Joon Seop Lee, Sung Kook Kim, Yun Jin Jung, Sang-Bum Kang, Manasi Agrawal, Ryan Ungaro, Jean-Frederic Colombel
    Digestive Diseases and Sciences.2022; 67(7): 2866.     CrossRef
  • Cytomegalovirus in ulcerative colitis: an evidence-based approach to diagnosis and treatment
    Anuraag Jena, Shubhra Mishra, Anupam Kumar Singh, Aravind Sekar, Vishal Sharma
    Expert Review of Gastroenterology & Hepatology.2022; 16(2): 109.     CrossRef
  • Efficacy of sigmoidoscopy for evaluating disease activity in patients with ulcerative colitis
    Su Bum Park, Seong-Jung Kim, Jun Lee, Yoo Jin Lee, Dong Hoon Baek, Geom Seog Seo, Eun Soo Kim, Sang-Wook Kim, So Yeong Kim
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Identification of useful genes from multiple microarrays for ulcerative colitis diagnosis based on machine learning methods
    Lin Zhang, Rui Mao, Chung Tai Lau, Wai Chak Chung, Jacky C. P. Chan, Feng Liang, Chenchen Zhao, Xuan Zhang, Zhaoxiang Bian
    Scientific Reports.2022;[Epub]     CrossRef
  • Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
    Kyuwon Kim, Hee Seung Hong, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, Sang Hyoung Park
    The Korean Journal of Internal Medicine.2022; 37(6): 1140.     CrossRef
  • Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis
    Soo-Kyung Park, Sang-Bum Kang, SangSoo Kim, Tae Oh Kim, Jae Myung Cha, Jong Pil Im, Chang Hwan Choi, Eun Soo Kim, Geom Seog Seo, Chang Soo Eun, Dong Soo Han, Dong Il Park
    The Korean Journal of Internal Medicine.2022; 37(5): 949.     CrossRef
  • Physician education can minimize inappropriate steroid use in patients with inflammatory bowel disease: the ACTION study
    Yehyun Park, Chang Hwan Choi, Hyun Soo Kim, Hee Seok Moon, Do Hyun Kim, Jin Ju Kim, Dennis Teng, Dong Il Park
    Intestinal Research.2022; 20(4): 452.     CrossRef
  • Corticosteroid, a double-edged sword in inflammatory bowel disease management: possibility of reducing corticosteroid use through physician education
    Seulji Kim, Seong-Joon Koh
    Intestinal Research.2022; 20(4): 389.     CrossRef
  • La escala control nutricional (CONUT): una herramienta prometedora para el cribado nutricional y como predictor de severidad en la colitis ulcerosa crónica idiopática
    J.L. de-León-Rendón, R.Y. López-Pérez, N.I. Gracida-Mancilla, B. Jiménez-Bobadilla, L. Alarcón-Bernés, S. Mendoza-Ramírez, J.A. Villanueva-Herrero
    Revista de Gastroenterología de México.2021; 86(2): 110.     CrossRef
  • Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
    Jae Hee Cheon
    Journal of Rheumatic Diseases.2021; 28(1): 4.     CrossRef
  • Tumor Necrosis Factor-Alpha Inhibitor-Associated Psoriatic Alopecia in a Patient with Ulcerative Colitis: A Case Report and Review of the Literature
    Kyung Muk Jeong, Ji Yun Seo, Anna Kim, Yoo Sang Baek, Hae Jun Song, Jiehyun Jeon
    Annals of Dermatology.2021; 33(1): 82.     CrossRef
  • The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis
    Yujin Jeong, Seong Ran Jeon, Hyun Gun Kim, Jung Rock Moon, Tae Hee Lee, Jae Young Jang, Jun-Hyung Cho, Jun Seok Park, Heesu Park, Ki-hun Lee, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Suyeon Park
    Intestinal Research.2021; 19(1): 62.     CrossRef
  • Comparative Study of Anti-Inflammatory Effect on DSS-Induced Ulcerative Colitis Between Novel Glycyrrhiza Variety and Official Compendia
    Sa-Haeng Kang, Young-Jae Song, Yong-Deok Jeon, Dong-Keun Kim, Jeong-Hyang Park, Ju-Ryoun Soh, Jong-Hyun Lee, Christopher Kitalong, Wonnam Kim, Hyo-Jin An, Jae-Ki Chang, Jeonghoon Lee, Jong-Sik Jin
    Applied Sciences.2021; 11(4): 1545.     CrossRef
  • McN-A-343, a muscarinic agonist, reduces inflammation and oxidative stress in an experimental model of ulcerative colitis
    Diva de Aguiar Magalhães, Jalles Arruda Batista, Stefany Guimarães Sousa, Jayro dos Santos Ferreira, Lauanda da Rocha Rodrigues, Cynthia Maria Carvalho Pereira, José Victor do Nascimento Lima, Ieda Figueira de Albuquerque, Nayonara Lanara Sousa Dutra Beze
    Life Sciences.2021; 272: 119194.     CrossRef
  • Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
    Yong Il Lee, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
    Gut and Liver.2021; 15(2): 232.     CrossRef
  • The controlling nutritional status score: A promising tool for nutritional screening and predicting severity in ulcerative colitis patients
    J.L. de-León-Rendón, R.Y. López-Pérez, N.I. Gracida-Mancilla, B. Jiménez-Bobadilla, L. Alarcón-Bernés, S. Mendoza-Ramírez, J.A. Villanueva-Herrero
    Revista de Gastroenterología de México (English Edition).2021; 86(2): 110.     CrossRef
  • Comparison of outcomes of cyclosporine A and infliximab for steroid‐refractory acute severe ulcerative colitis
    Eun Mi Song, Eun Hye Oh, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang, Byong Duk Ye
    Journal of Gastroenterology and Hepatology.2021; 36(9): 2463.     CrossRef
  • Clinical Significance of Residual Nonrectal Inflammation in Ulcerative Colitis Patients in Clinical Remission
    Jongbeom Shin, Sung Min Kong, Tae Jun Kim, Eun Ran Kim, Sung Noh Hong, Dong Kyung Chang, Young-Ho Kim
    Gut and Liver.2021; 15(3): 401.     CrossRef
  • The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study
    Byong Duk Ye, Jae Hee Cheon, Ki Hwan Song, Joo Sung Kim, Young-Ho Kim, Hyuk Yoon, Kang-Moon Lee, Sang-Bum Kang, Byung Ik Jang, Jae Jun Park, Tae Oh Kim, Dae-Wook Lee, Chee Yoong Foo, Jeong Eun Shin, Dong Il Park
    Therapeutic Advances in Gastroenterology.2021;[Epub]     CrossRef
  • Efficacy and safety of Etiasa for treatment of mild-to-moderate ulcerative colitis: A Meta-analysis
    Fang-Mei Ling, Fei-Nan Lu, Sheng-Nan Wang, Liang-Ru Zhu
    World Chinese Journal of Digestology.2021; 29(15): 880.     CrossRef
  • Draft Genome Sequence of Paraclostridium bifermentans subsp. muricolitidis Strain PAGU 1678 T , Which Exacerbates Pathosis in a Mouse Model of Ulcerative Colitis
    Ryo Kutsuna, Tohru Miyoshi-Akiyama, Junko Tomida, Yoshiaki Kawamura, Steven R. Gill
    Microbiology Resource Announcements.2021;[Epub]     CrossRef
  • Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
    You Sun Kim
    Journal of the Korean Medical Association.2021; 64(9): 596.     CrossRef
  • Is fasting beneficial for hospitalized patients with inflammatory bowel diseases?
    Yong Eun Park, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jung Nam Kim, Na Rae Lee, Jae Hee Cheon
    Intestinal Research.2020; 18(1): 85.     CrossRef
  • Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
    Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
    Digestive Diseases and Sciences.2020; 65(5): 1436.     CrossRef
  • Fecal calprotectin is more accurate than fecal immunochemical test for predicting mucosal healing in quiescent ulcerative colitis: a prospective multicenter study
    Eun Soo Kim, Hyun Seok Lee, Sung Kook Kim, Eun Young Kim, Byung Ik Jang, Kyeong Ok Kim, Chang Heon Yang, Yoo Jin Lee
    Scandinavian Journal of Gastroenterology.2020; 55(2): 163.     CrossRef
  • Multidirectional Pharma-Toxicological Study on Harpagophytum procumbens DC. ex Meisn.: An IBD-Focused Investigation
    Lucia Recinella, Annalisa Chiavaroli, Maurizio Ronci, Luigi Menghini, Luigi Brunetti, Sheila Leone, Bruno Tirillini, Paola Angelini, Stefano Covino, Roberto Venanzoni, Gokhan Zengin, Simonetta Di Simone, Maria Chiara Ciferri, Viviana di Giacomo, Amelia Ca
    Antioxidants.2020; 9(2): 168.     CrossRef
  • Pregnancy outcomes in women with inflammatory bowel disease: a 10‐year nationwide population‐based cohort study
    Han H. Lee, Jung Min Bae, Bo‐In Lee, Kang‐Moon Lee, Jeong H. Wie, Jin S. Kim, Young‐Seok Cho, Sung‐Ae Jung, Sang W. Kim, Hwang Choi, Myung‐Gyu Choi
    Alimentary Pharmacology & Therapeutics.2020; 51(9): 861.     CrossRef
  • Effect of Age on the Initiation of Biologic Agent Therapy in Patients With Inflammatory Bowel Disease: Korean Common Data Model Cohort Study
    Youn I Choi, Yoon Jae Kim, Jun-Won Chung, Kyoung Oh Kim, Hakki Kim, Rae Woong Park, Dong Kyun Park
    JMIR Medical Informatics.2020; 8(4): e15124.     CrossRef
  • Mechanism-based Drug Therapy of Inflammatory Bowel Disease With Special Reference to Rheumatic Disease
    Jae Jun Park
    Journal of Rheumatic Diseases.2020; 27(3): 128.     CrossRef
  • Sarcopenia Is a New Risk Factor of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease
    Min Kyu Kang, Kyeong Ok Kim, Min Cheol Kim, Jung Gil Park, Byung Ik Jang
    Digestive Diseases.2020; 38(6): 507.     CrossRef
  • Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases
    Minkyung Han, Yoon Suk Jung, Jae Hee Cheon, Sohee Park
    Journal of Gastroenterology and Hepatology.2019; 34(7): 1166.     CrossRef
  • Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study
    Soo-Kyung Park, Sang Hyun Park, Chang Soo Eun, Geom Seog Seo, Jong Pil Im, Tae Oh Kim, Dong-Il Park
    Intestinal Research.2019; 17(3): 349.     CrossRef
  • Two-year delay in ulcerative colitis diagnosis is associated with anti-tumor necrosis factor alpha use
    Ho Suk Kang, Ja-Seol Koo, Kang Moon Lee, Dae-Bum Kim, Ji Min Lee, Yoon Jae Kim, Hyuk Yoon, Hyun Joo Jang
    World Journal of Gastroenterology.2019; 25(8): 989.     CrossRef
  • A Real-World Analysis of Prescribing Patterns and Non-persistence of Anti-TNFα Therapy for Inflammatory Bowel Disease
    Eun Jin Jang, Jung Eun Ha, Seul Gi Im, Myeong Gyu Kim, Hyun Soon Sohn
    Clinical Drug Investigation.2019; 39(7): 625.     CrossRef
  • Medication Use and Drug Expenditure in Inflammatory Bowel Disease: based on Korean National Health Insurance Claims Data (2010-2014)
    Jung Eun Ha, Eun Jin Jang, Seul Gi Im, Hyun Soon Sohn
    Korean Journal of Clinical Pharmacy.2019; 29(2): 79.     CrossRef
  • Protective effects induced by alcoholic Phlomis fruticosa and Phlomis herba‐venti extracts in isolated rat colon: Focus on antioxidant, anti‐inflammatory, and antimicrobial activities in vitro
    Claudio Ferrante, Lucia Recinella, Maurizio Ronci, Giustino Orlando, Simonetta Di Simone, Luigi Brunetti, Annalisa Chiavaroli, Sheila Leone, Matteo Politi, Bruno Tirillini, Paola Angelini, Stefano Covino, Roberto Venanzoni, Sanda Vladimir‐Knežević, Luigi
    Phytotherapy Research.2019; 33(9): 2387.     CrossRef
  • Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation
    Seong Ran Jeon, Jocelyn Chai, Christiana Kim, Christine H. Lee
    Current Infectious Disease Reports.2018;[Epub]     CrossRef
  • Monitoring Disease Activity: How and When?
    Kang-Moon Lee
    The Korean Journal of Gastroenterology.2018; 71(2): 69.     CrossRef
  • Novel treatments for inflammatory bowel disease
    Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
    The Korean Journal of Internal Medicine.2018; 33(1): 20.     CrossRef
  • How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?
    You Sun Kim
    The Korean Journal of Gastroenterology.2018; 71(2): 74.     CrossRef
  • Endoscopic Transplantation of Mesenchymal Stem Cell Sheets in Experimental Colitis in Rats
    Sehyung Pak, Sung Wook Hwang, In Kyong Shim, Sang Mun Bae, Yeon- Mi Ryu, Han-Byul Kim, Eun-ju Do, Hye-Nam Son, Eun-ji Choi, Sun-ha Park, Sang-Yeob Kim, Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang, Nobuo Kanai, Masanori Maeda, Teruo Okano, Dong-Hoon Yang
    Scientific Reports.2018;[Epub]     CrossRef
  • Is once daily multimatrix mesalazine therapy effective regardless of the dose in patients with mild to moderate ulcerative colitis?
    Seong Ran Jeon
    Intestinal Research.2018; 16(2): 163.     CrossRef
  • Is Clostridium difficile infection a real threat in patients with ulcerative colitis? A prospective, multicenter study in Korea
    Dae Bum Kim, Kang-Moon Lee, Sang Hyoung Park, You Sun Kim, Eun Soo Kim, Jun Lee, Sung-Ae Jung, Geom Seog Seo, Ji Min Lee
    Intestinal Research.2018; 16(2): 267.     CrossRef
  • Mesenchymal Stromal Cells in the Treatment of Perianal Fistulas in Crohn'S Disease
    Jesús Castro-Poceiro, Agnès Fernández-Clotet, Julián Panés
    Immunotherapy.2018; 10(14): 1203.     CrossRef
  • Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia: A Randomized, Controlled Trial
    Hyuk Yoon, Dong Ho Lee, Yong-Hyun Lee, Ju-Cheol Jeong, Soo Teik Lee, Myung-Gyu Choi, Seong Woo Jeon, Ki-Nam Shim, Gwang Ho Baik, Jae Gyu Kim, Jeong Seop Moon, In-Kyung Sung, Sang Kil Lee, Poong-Lyul Rhee, Hwoon-Yong Jung, Bong Eun Lee, Hyun Soo Kim, Sang
    Gut and Liver.2018; 12(5): 516.     CrossRef
  • Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?
    Jihye Park, Jae Hee Cheon
    Intestinal Research.2017; 15(3): 263.     CrossRef
  • Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy
    Way-Seah Lee, Najib Azmi, Ruey-Terng Ng, Sik-Yong Ong, Sasheela Sri La Ponnampalavanar, Sanjiv Mahadeva, Ida Hilmi
    Intestinal Research.2017; 15(4): 524.     CrossRef
  • 17,581 View
  • 217 Download
  • 61 Web of Science
  • 63 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP